Biosimilar/Biotech Programs
Not Specified
ResearchActive
Key Facts
About Deva Holdings
Founded in 1958, Deva Holdings has grown from a domestic Turkish pharmaceutical player into an internationally recognized, publicly traded generics and API manufacturer. Its strategy is built on vertical integration, a strong R&D focus on bioequivalence, and geographic expansion into over 80 countries. Key achievements include establishing a significant export business, maintaining a diverse portfolio spanning multiple therapeutic areas, and operating a large-scale, end-to-end production infrastructure. The company's mission, 'For lives we add health to...', underscores its commercial focus on affordable, accessible medicine.
View full company profileTherapeutic Areas
Other Not Specified Drugs
| Drug | Company | Phase |
|---|---|---|
| FL116 | Forlong Biotechnology | Not specified |
| FL117 | Forlong Biotechnology | Not specified |
| FL118 | Forlong Biotechnology | Not specified |
| FL301 | Forlong Biotechnology | Not specified |
| JSKN016 | AlphaMab Oncology | Phase 1 |
| JSKN033 | AlphaMab Oncology | Phase 1 |
| JSKN022 | AlphaMab Oncology | Phase 1 |
| JSKN027 | AlphaMab Oncology | Phase 1 |
| KN019 | AlphaMab Oncology | Phase 1 |
| New TCM Formulations | China SXT Pharmaceuticals | Research / Pre-clinical |
| Long-acting Leronlimab | CytoDyn | Preclinical |
| SR2162 | SIMR (Australia) Biotech | IND Approved |